Researchers are apparently “this close” to finalizing a rapid (less than 3 minutes) prostate biomarker screen. Throughout much of this decade the development of organic biomarkers to stage disease and stratify risk has become an important part of medical research, particularly that research conducted via nanotechnology.

Designed to ultimately replace comparably less efficient methods of testing for the same results (in this case, prostatic fluid anion determination as a surrogate marker for tumor growth), the test’s major drawback is that it is invasive. The physician has to use a needle aspirate to directly obtain the fluid from the prostate. 

Sounds promising, but needs to be tested across a wide population to establish utility — something that may be a tough sell to patients who will always need this test followed by an even more confirmatory invasive procedure, the biopsy. | LINK

Related Posts Within Doctor Pundit:

1. Researchers Find Imaging Technique Useful in Staging Cognitive Decline Of course, we’re light years away from using MRIs as...
2. Does Prostate Cancer Screening Overdiagnose Cancer? Here’s an age-old question: do too many men have prostate...
3. Patient Advocacy Group on Prostate Cancer Gets Serious about Prevention – Zero prostate cancer deaths. Zero prostate cancer cases and for...
4. CMS to Weigh in on Coverage of Certain Prostate Cancer Treatments On Wednesday a private party empaneled by CMS will begin...
5. Researchers Closer Than Ever in Targeted Anti-Alzheimer Therapeutic Research As Doctor Pundit has always reported in this space, the...